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Nitroglycerine triggers triptan-responsive
cranial allodynia and trigeminal
neuronal hypersensitivity
Simon Akerman,1,2,3,* Nazia Karsan,4,5,* Pyari Bose,4,5 Jan R. Hoffmann,1,4
Philip R. Holland,4 Marcela Romero-Reyes2,3 and Peter J. Goadsby1,4,5
*These authors contributed equally to this work.
See De Icco and Tassorelli (doi:10.1093/brain/awy315) for a scientiﬁc commentary on this article.
Cranial allodynia associated with spontaneous migraine is reported as either responsive to triptan treatment or to be predictive of
lack of triptan efﬁcacy. These conﬂicting results suggest that a single mechanism mediating the underlying neurophysiology of
migraine symptoms is unlikely. The lack of a translational approach to study cranial allodynia reported in migraine patients is a
limitation in dissecting potential mechanisms. Our objective was to study triptan-responsive cranial allodynia in migraine patients,
and to develop an approach to studying its neural basis in the laboratory. Using nitroglycerine to trigger migraine attacks, we
investigated whether cranial allodynia could be triggered experimentally, observing its response to treatment. Preclinically, we
examined the cephalic response properties of central trigeminocervical neurons using extracellular recording techniques, determin-
ing changes to ongoing ﬁring and somatosensory cranial-evoked sensitivity, in response to nitroglycerine followed by triptan
treatment. Cranial allodynia was triggered alongside migraine-like headache in nearly half of subjects. Those who reported cranial
allodynia accompanying their spontaneous migraine attacks were signiﬁcantly more likely to have symptoms triggered than those
that did not. Patients responded to treatment with aspirin or sumatriptan. Preclinically, nitroglycerine caused an increase in
ongoing ﬁring and hypersensitivity to intracranial-dural and extracranial-cutaneous (noxious and innocuous) somatosensory stimu-
lation, reﬂecting signatures of central sensitization potentially mediating throbbing headache and cranial allodynia. These responses
were aborted by a triptan. These data suggest that nitroglycerine can be used as an effective and reliable method to trigger cranial
allodynia in subjects during evoked migraine, and the symptom is responsive to abortive triptan treatments. Preclinically, nitro-
glycerine activates the underlying neural mechanism of cephalic migraine symptoms, central sensitization, also predicting the
clinical outcome to triptans. This supports a biological rationale that several mechanisms can mediate the underlying neurophysi-
ology of migraine symptoms, with nitrergic-induced changes reﬂecting one that is relevant to spontaneous migraine in many
migraineurs, whose symptoms of cranial allodynia are responsive to triptan treatment. This approach translates directly to re-
sponses in animals and is therefore a relevant platform to study migraine pathophysiology, and for use in migraine drug discovery.
1 Headache Group-Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA
2 Department of Oral and Maxillofacial Pathology, Radiology and Medicine, New York University College of Dentistry, New York,
NY 10010, USA
3 Department of Neural and Pain Sciences, University of Maryland Baltimore, Baltimore, Maryland, MD 21201, USA
4 Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychology, Psychiatry and Neuroscience, King’s
College London, London, SE5 9NU, UK
5 NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London, SE5 9PJ, UK
Correspondence to: Dr Simon Akerman
Department of Neural and Pain Sciences
University of Maryland Baltimore
doi:10.1093/brain/awy313 BRAIN 2019: 142; 103–119 | 103
Received July 12, 2018. Revised September 26, 2018. Accepted October 23, 2018
 The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/1/103/5263733 by King's C
ollege London user on 20 M
arch 2019
650W. Baltimore Street
Baltimore, MD 21201, USA
E-mail: sakerman@umaryland.edu or simon.akerman@gmail.com
Correspondence may also be addressed to: Professor Peter Goadsby
NIHR-Wellcome Trust King’s Clinical Research Facility
King’s College Hospital
London
SE5 9PJ, UK
E-mail: peter.goadsby@kcl.ac.uk
Keywords: nitroglycerine; cutaneous allodynia; trigeminovascular; hypersensitivity, central sensitization
Abbreviation: VIP = vasoactive intestinal peptide
Introduction
Migraine headache is thought to be the result of abnormal
activation and sensitization (Noseda and Burstein, 2013), or
the perception of activation (Akerman et al., 2011; Goadsby
et al., 2017), of trigeminal primary afferents innervating the
nociceptive producing dural vasculature and their central
projections to the medullary dorsal horn and upper cervical
spinal cord (Noseda and Burstein, 2013; Goadsby et al.,
2017). Sensitization of these dural-responsive trigeminovas-
cular neurons, which also receive inputs from facial cutane-
ous areas, is thought to cause extracranial facial
hypersensitivity manifesting as cutaneous allodynia and
hyperalgesia in migraine patients (Burstein et al., 2000).
These symptoms affect up to two-thirds of migraine patients
(Selby and Lance, 1960; Lipton et al., 2008). Studies in mi-
graineurs offer unique insights into the importance of trige-
minovascular sensitization in migraine pathophysiology, with
the presence and severity of cranial allodynia being a marker
of susceptibility to chronic migraine (Bigal et al., 2008).
As a symptom, cranial allodynia is an important substrate
against which to evaluate abortive treatment response, both
clinically and preclinically. This is because patient responses
to acute treatments vary. In some reports patients with allo-
dynia remain responsive to triptans (Cady et al., 2007;
Schoenen et al., 2008; Diaz-Insa et al., 2011), whereas in
others the presence of cranial allodynia predicts the lack of
triptan efﬁcacy (Burstein et al., 2004; Jakubowski et al.,
2005a). These conﬂicting outcomes suggest that the under-
lying mechanism of cranial allodynia in migraine cannot be
fully explained by a single process. The lack of an effective
and reliable translational approach to study cranial allodynia
is a limitation in dissecting the mechanisms involved, with
current studies relying on capturing spontaneous attacks
while patients are visiting the headache clinic. Existing
human migraine models, using exogenously administered sub-
stances, provide a unique and attractive opportunity to study
the disorder (Ashina et al., 2017). Nitroglycerine is the most
established method to study migraine, triggering a delayed
migraine-like headache in a high proportion of migraineurs
(Iversen et al., 1989), alongside non-painful premonitory
symptoms (Afridi et al., 2004; Maniyar et al., 2014). It also
produces activation in brain areas on functional brain ima-
ging, similar to those demonstrated during spontaneous mi-
graine (Bahra et al., 2001; Afridi et al., 2005). However,
other phenotypic symptoms, such as cranial allodynia, have
not been captured previously in such studies.
Here our aim was to determine whether nitroglycerine can
trigger cranial allodynia associated with migraine, and subse-
quently the effectiveness of standard migraine abortive treat-
ment with aspirin or sumatriptan, to relieve these symptoms.
We also wanted to determine the translational potential of
nitroglycerine as a trigger of migraine-associated cranial allo-
dynia, by studying its neural basis and efﬁcacy as a preclinical
model. Nitroglycerine in rodents induces neuronal activation
in similar brain areas (Tassorelli and Joseph, 1995;
Koulchitsky et al., 2004), and produces hind-paw and cranial
cutaneous allodynia (Pradhan et al., 2014; Marone et al.,
2018). However, its ability to trigger neurophysiological
mechanisms within central trigeminovascular neurons that
manifest as the neural mechanism of cephalic symptoms is
unknown. Using electrophysiological recording of central tri-
geminocervical neurons, we analysed the neurophysiological
changes caused by nitroglycerine on spontaneous ﬁring and
whether this manifested as neuronal hypersensitivity to som-
atosensory cranial stimulation. To validate this approach, we
used delayed abortive treatment with a triptan to determine if
it also predicted the clinical outcomes observed in both spon-
taneous migraine, and the nitroglycerine human model.
Materials and methods
Clinical studies
Study population and screening process
The study was carried out with research ethics approval
by Camden and King’s Cross Ethics Committee (reference
15/LO/2241), and had Research and Development Approval
at King’s College Hospital. Telephone interviews were con-
ducted to prescreen patients (n = 335) that responded via e-
mail to online and paper bulletins within migraine-related
media. Inclusion and exclusion criteria (Supplementary Table
1), including age (18–50 years), diagnosis for migraine with or
without aura (Headache Classiﬁcation Committee of the
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International Headache Society, 2013), elimination of possible
secondary cause of headache, presence of another chronic pain
disorder or confounding medical condition, previous response
to abortive medications used in the study, and contraindica-
tions to nitroglycerine infusion, were reviewed. Eligible pa-
tients (n = 53) were then invited to a ﬁrst visit (Visit 1),
where a study investigator conducted a full medical and
family history, headache features and associated symptoms,
with brief physical examination. Allodynia history was asked
as a single question ‘Do you have abnormally high sensitivity
of the skin of your scalp to touch during a migraine attack?’,
and the response explored by a trained headache physician for
clarity. Subjects meeting all criteria were explained they would
be exposed to nitroglycerine infusion that might trigger mi-
graine symptoms, and they were given an opportunity to ask
any further questions, prior to providing informed consent.
Study design and procedures
Overall subjects made three or four study visits, depending on
treatment arm: sumatriptan or aspirin, respectively, including
placebo visit (vehicle for nitroglycerine), and the remainder
involved migraine triggering with nitroglycerine. The reason
for the mixed visit design was based on the initial study testing
triptan response only. Another aspirin/placebo arm was
included because of triptan non-responders based on spontan-
eous attacks. On Visit 1 subjects were entered into either treat-
ment group, based on their preferred and usual successful
response to each agent or drug class: triptan or non-steroidal
anti-inﬂammatory drug (NSAID), with spontaneous attacks,
and relative contraindications. Sumatriptan was chosen as it
is the most commonly prescribed of the triptans and is avail-
able in injectable form with rapid onset of action, and aspirin
similarly as it can also be administered intravenously, and be-
cause it is a highly effective NSAID for migraine abortion
(Weatherall et al., 2010). Subjects who had previously not re-
sponded to triptans or NSAID medications were excluded.
Nitroglycerine (0.5 mg/kg/min) was intravenously infused over
20min via the hand, forearm or antecubital fossa, using a 20–
22G standard intravenous cannula. Subjects remained ﬂat
during infusion to limit nitroglycerine-induced hypotension,
and were asked not to eat and drink in case of nausea and
vomiting accompanying the migraine attack. Hydration was
provided through a 125ml/h, 5% dextrose/0.9% normal
saline infusion following nitroglycerine. Subjects were moni-
tored for the development of migraine headache and associated
symptoms, along with blood pressure and heart rate prior to
infusion, every 5min during infusion, and subsequently every
15 min following infusion. If/when migraine-like headache
reached moderate-severe intensity, subjects were treated with
either sumatriptan [6 mg, subcutaneously (s.c.)] or aspirin [1 g,
intravenous (i.v.)]. Subjects with successful nitroglycerine-trig-
gered migraine-like headaches were invited back for subse-
quent visits, where they were exposed again to nitroglycerine
or placebo. All conditions and questioning/monitoring were
the same on each visit. This timeline is summarized in
Supplementary Fig. 1. For the purposes of treating migraine,
as the initial study was designed for a functional neuroimaging
study, there was a delay in treating headache when it did reach
moderate-severe intensity. In addition, consistent with other
nitroglycerine provocation studies in the literature, the mi-
graine headache ensued at a delayed time point following
nitroglycerine infusion (Ashina et al., 2017).
On all subsequent visits following Visit 1, all subjects were
either exposed to nitroglycerine or placebo as the ‘triggering’
agent in a double-blind randomized design. This design was
used to ensure that the symptoms experienced by subjects fol-
lowing infusion were truly attributable to the nitroglycerine-
induced migraine process rather than a placebo effect.
Patient questioning and monitoring
Each subject was monitored in the facility for at least 5 h after
the start of the infusion for the development of headache symp-
toms, and their subsequent response to abortive medication,
until complete resolution of pain. To allow direct comparison
of migraine phenotype, a standardized physician-administered
symptom questionnaire of headache and associated features,
including those of premonitory, aura, allodynia, vertigo, and
postdrome, was used to collect data regarding previous spon-
taneous attacks, and the evolution of triggered attacks, across
each study visit. In particular, as migraine-like headache reached
moderate-severe intensity, subjects were asked: (i) ‘Do you have
abnormally high sensitivity of the skin of your scalp to touch at
the moment?’; and (ii) ‘Does this feel like the sensation you
experience during one of your spontaneous attacks?’
Subjects were monitored until complete pain resolution. An
improvement in allodynia was documented in answer to the
question: ‘Has the sensitivity of the skin on your scalp com-
pletely resolved?’ An answer ‘yes’ was documented as treat-
ment response, and any residual allodynia after treatment was
documented as a failure of treatment.
Migraine headache was deﬁned as suggested by the modiﬁed
criteria for a pharmacologically provoked experimental mi-
graine headache (Ashina et al., 2013), summarized in Table 1.
At the end of the study recording, rescue medication for pain
and/or nausea with paracetamol (acetaminophen), ibuprofen,
sumatriptan, aspirin, domperidone and ondansetron were add-
itionally available.
Statistical analysis
Associations between qualitative variables were analysed with
the Cohen’s kappa measure of association. Binary logistic re-
gression was used to analyse the effect of headache frequency,
age, years with migraine, and diagnosis on allodynia trigger-
ing, and presented as odds ratios (OR) and conﬁdence inter-
vals (CI). Analyses for the reproducibility of allodynia
triggering were only performed for up to two exposures to
nitroglycerine. The differences in allodynia response to the
two different treatments were not statistically tested here due
to small sample size in each subgroup. Signiﬁcance was as-
sessed at the P5 0.05 level (IBM-SPSS 24.0).
Preclinical studies
All experiments were conducted in compliance of a research
protocol approved by the UCSF or NYU Institutional Animal
Care and Use Committee, and conforming to the National
Institute of Health Guide for the Care and Use of
Laboratory Animals, adhering to ARRIVE guidelines and
those of the Committee for Research and Ethical Issues of
IASP (Zimmermann, 1983).
Animals and experimental design
The animals per group was based on published data and
previous experience that typically sees difference in means
Triptan-responsive cranial allodynia BRAIN 2019: 142; 103–119 | 105
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/1/103/5263733 by King's C
ollege London user on 20 M
arch 2019
of 25–30% [standard deviation (SD) = 15–20%] with a two-
sided alpha of 0.05 and power of 80%, which requires
sample size of 10–12 animals to measure time points up to
3 h. We used male Sprague-Dawley rats (250–390 g) through-
out these studies. Prior to the day of study they were housed
in temperature and light controlled rooms for at least 7 days,
with ad libitum access to food and water. Each experimental
group within a series was assigned an integer and all rats
were randomly assigned to the different experimental proto-
cols and drug groups using the Microsoft Excel random
number generator with the parameters set by the number of
groups. We worked through these groups in the order
assigned by the random number generator and studies were
operator blinded with respect to chemical intervention, to
avoid bias.
Animal preparation and electrophysiological
recording
The surgical preparation, physiological monitoring, electro-
physiological recording methods and analyses are the same
as those reported in detail previously (Akerman et al., 2010;
Akerman and Goadsby, 2015). Brieﬂy, rats were anaesthetized
with sodium pentobarbital (Nembutal, 60–70mg/kg, intra-
peritoneal) and maintained with propofol (PropoFloTM, 15–
25mg/kg/h i.v. infusion), and prepared for electrophysiological
extracellular recording of dural-responsive neurons in the tri-
geminocervical complex. Blood pressure, body temperature
and expired CO2 were continuously monitored and kept
within physiological limits. During electrophysiological record-
ing animals were paralysed with pancuronium bromide
(Pavulon, Organon) 0.4mg initially and maintained with
0.2mg every 35min. A sufﬁcient depth of anaesthesia was
judged by the absence of paw withdrawal and corneal blink
reﬂex, and during muscular paralysis by ﬂuctuations of blood
pressure and changes to expired CO2.
Characterization of neurons
A tungsten recording electrode (0.5–1M, tip diameter
0.5 mm) was advanced into the trigeminocervical complex
region at 5-mm increments. Neuronal responses were charac-
terized for their cutaneous and deep receptive ﬁeld, and were
assessed through all three trigeminal territories for both nox-
ious and non-noxious responses, as the recording electrode
advanced through the spinal cord. Neurons identiﬁed as
having cutaneous receptive ﬁelds within the ophthalmic facial
dermatome were then tested for convergent nociceptive input
from the trigeminal innervation of the dura mater.
Nociceptive-responsive trigeminal afferents were activated
using electrical stimulation of the dura mater using square-
wave stimuli (100–200 ms pulse, 0.25Hz and 8–15V). By
moving the bipolar stimulating electrode around the dural re-
ceptive ﬁeld and recording responses to electrical stimuli we
were able to establish its optimal position to produce reliable
and signiﬁcant evoked action potential spikes. The distinction
of trigeminal Ad (‘fast’ responses) and C-ﬁbres (‘slow’ re-
sponses) that innervate the dura mater is based on the approxi-
mate conduction velocities of Ad (2.0–30.0m/s) and C-ﬁbres
(0.5–2.0m/s) (Millan, 1999) and the distance from the dural
stimulation site to the trigeminocervical complex recording site
(30–40mm) (Akerman and Goadsby, 2015). Facial receptive
ﬁeld characterization consisted of 10 brush strokes applied to
the facial receptive ﬁeld over 7–8 s for the innocuous response,
and pinch with forceps for 4 s for the noxious response.
Spontaneous activity (spikes per second, Hz) was recorded
throughout and measures for analysis taken for 300 s preced-
ing the dural stimulation. Post and peri-stimulus time histo-
grams of neural activity were displayed and analysed using
Spike2 v8.
Drugs
Nitroglycerine (American Regent, Inc) was dissolved in 30%
alcohol, 30% propylene glycol and water in a stock solution
of 5mg/ml. Nitroglycerine (10mg/kg) was administered
(0.6ml, s.c.) at the neck scruff, given slowly over 2–3min,
and neural responses monitored for 3 h. This dose has been
shown previously to be optimal to produce neuronal activation
along the migraine pain pathway in rats (Tassorelli and
Joseph, 1995) and craniofacial allodynia (Marone et al.,
2018). Nitroglycerine (1mg/kg, s.c.), was used as a low dose
control, and vasoactive intestinal peptide (VIP, Tocris Cookson
Ltd) (Akerman and Goadsby, 2015), dissolved in saline
(150 mg/kg, s.c.), was used as a control for the potential vas-
cular effects of nitroglycerine. Naratriptan hydrochloride
(Connor et al., 1997; Cumberbatch et al., 1998) (10mg/kg
in water; GlaxoSmithKline) was used to determine if a triptan
can reverse the nitroglycerine-induced trigeminovascular
Table 1 The modified migraine criteria for migraine-like headache attack in experimental studies
Diagnose Migraine-like attack after pharmacological provocation
Diagnostic criteria (1) Headache fulfilling ICHD-II criteria C and D for migraine without aura
C) Headache has at least two of the following characteristics
(1) Unilateral location
(2) Pulsating quality
(3) Moderate or severe pain intensity (44 on VRS)
(4) Aggravation by cough (in-hospital phase) or causing the avoidance of routine activity (out-hospital phase)
(e.g. walking or climbing stairs)
D) During headache at least one of the following
(1) Nausea and/or vomiting
(2) Photophobia and phonophobia
(1) Headache described as mimicking usual migraine attack and treated with triptan/aspirin
Taken and adapted from Headache Classification Committee of the International Headache Society (2004) and Ashina et al. (2013). VRS = Verbal Rating Scale.
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changes, 135min after nitroglycerine administration. We chose
naratriptan as we have used this extensively in previous pre-
clinical studies; doing so would thus allow us to compare our
new data with those from previous studies. This, or similar
doses, do not affect normal spinal nociceptive processing
(Connor et al., 1997; Cumberbatch et al., 1998). This dose
is similar to that used in previous preclinical studies that
observed 50% or greater inhibition of neuronal responses
that are prolonged for up to 45min, and reﬂects the relative
binding afﬁnity at 5-HT1B/1D rat receptors, which is lower
compared to humans.
Statistical analysis
Analysis of blood pressure changes across groups was made
using a one-way ANOVA followed by independent two-tailed
t-tests, where necessary. The exact latency of neuronal dis-
charges was established separately in each experiment and
this latency window used throughout. The data collected
from post-stimulus histograms represents the number of
action potential spikes that ﬁred within a latency window
per stimulation, averaged over 20 stimulations (sweeps;
spikes/sweep, s/s). Cutaneous receptive ﬁeld responses and on-
going spontaneous neuronal activity are measured in cell ﬁr-
ings per second (Hz). All data are expressed as
mean  standard error of the mean (SEM). Statistical analysis
was performed using ANOVA for repeated measures with
Bonferroni post hoc correction for multiple comparisons to
measure the time course of signiﬁcant drug intervention,
using a 95% CI. If Mauchly’s test of sphericity was violated
we made appropriate corrections to degrees of freedom ac-
cording to Greenhouse-Geisser. Student’s paired two-tailed t-
test for post hoc analysis was used to test for the time points
of signiﬁcance, using the average of the two or three baselines
for comparison, again using the criteria of Bonferroni correc-
tion. Kruskal-Wallis test was used for non-parametric data,
where applicable. Statistical signiﬁcance was set at P5 0.05
(using IBM-SPSS 22.0 throughout).
Data availability
The authors conﬁrm that the data supporting the ﬁndings
of this study are available within the article and its
Supplementary material. Inquiries for additional data are
available from the corresponding authors, upon reasonable
request.
Results
Human studies and demographics
Of 335 patients prescreened for eligibility, 53 patients (18–
50 years, mean = 35 years) with migraine with or without
aura were recruited into the study, and each was exposed
to nitroglycerine at least once, having provided informed
consent. The range of previous headache days was 0–22
days per month (mean = 9 days). There were no contraindi-
cations to the use of nitroglycerine, aspirin or sumatriptan
treatment. Twenty-three subjects reported cranial allodynia
accompanying their spontaneous migraine (Table 2).
Subject demographics are summarized in Supplementary
Table 2.
Nitroglycerine triggers cranial
allodynia that responds to
abortive treatment
Visit 1
Of the 53 subjects, 44 had migraine headache triggered
with nitroglycerine and nine did not, although one had
left cranial allodynia triggered without moderate-severe
headache (Case 12); an 83% triggering rate. All cases
(53/53; 100%) experienced a mild bilateral headache asso-
ciated with the nitroglycerine infusion, which ceased soon
after the infusion was stopped. In those who developed a
migraine headache, this headache was delayed and worse in
severity, as well as being associated with other migraine-
deﬁning symptomatology, as outlined in the modiﬁed cri-
teria (Table 1). The time to onset of migraine headache
when categorized as either moderate or severe intensity
was 116.9  10min (range 20–278min, n = 44). Overall,
17 subjects reported headache-associated cranial allodynia
following nitroglycerine exposure (Tables 2 and 3).
Subjects who reported cranial allodynia accompanying
their spontaneous migraine attacks (13/20; 65%) were
more likely to have allodynia triggered with nitroglycerine
alongside their headache compared to those that did not
report cranial allodynia (4/24; 16%), Cohen’s kappa
measure of association, k = 0.445, P = 0.005, with 70%
reliability. A signiﬁcant number of these subjects (14/17
subjects, 82%, Cohen’s kappa measure of association,
k = 0.815, P5 0.001) responded to treatment with either
aspirin (n = 5/5) or sumatriptan (n = 9/12). Of note, the
one subject who developed allodynia without headache
following nitroglycerine exposure was not treated. There
was no signiﬁcant correlation between the reporting of
spontaneous allodynia and the success in triggering head-
ache with nitroglycerine (Cohen’s kappa = 0.155,
P = 0.144); i.e. the rate of triggered headache reporting
in the baseline allodynia and non-allodynic groups was
similar.
Subsequent visits
On subsequent visits patients were blinded to either nitro-
glycerine or placebo. Based on study design, there was the
opportunity for subjects to be exposed to nitroglycerine up
to three times. Of the initial 44 subjects, 17 of whom had
cranial allodynia, 24 were re-exposed to nitroglycerine a
second time and nine a third time. Because of the sequen-
tially reduced sample size across visits (due to drop outs
and the mixed design regarding number of study visits),
agreement analysis for allodynia reporting across visits
was only performed for up to two nitroglycerine exposures.
Of the 24 patients re-exposed to nitroglycerine, 23 de-
veloped migraine-like headache, and 14 of these had cra-
nial allodynia triggered (n = 14/23, 61%). Within this
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group, 10/12 (83%) patients had allodynia triggered on
their ﬁrst exposure also had allodynia symptoms triggered
on re-exposure, and 4/11 (36%) patients that did not have
allodynia triggered on ﬁrst exposure, did on the second
(Cohen’s kappa = 0.5, P = 0.021, 72% reliability). Overall,
10 patients with allodynia symptoms responded to the
abortive treatments (71%). Six patients had cranial allody-
nia triggered on their third visit (67%) and three responded
to treatment (50%). Note that on all blinded trigger visits,
no subjects developed migraine-like headache or cranial
allodynia with placebo infusion.
Overall summary
Of 86 exposures to nitroglycerine across repeated visits, 76
were treated with either aspirin or sumatriptan, and 37
included subjects experiencing allodynia with migraine-
like headache. Overall, in 28 of these 37 cases (76%) cu-
taneous allodynia was successfully treated, and in 15 of 21
cases (71%) sumatriptan successfully aborted allodynia. In
all cases of allodynia but one, the allodynia was associated
with moderate-severe headache either following or co-
occurring with its onset. The occurrence of allodynia fol-
lowing nitroglycerine provocation in this study is therefore
applicable to allodynia associated with spontaneous mi-
graine attacks.
Effects of diagnosis, age and
headache days
A binary logistic regression model was ﬁtted to the data to
investigate the relationship between age, headache fre-
quency, years with migraine and the outcomes of trig-
gered allodynia and reporting spontaneous allodynia at
Visit 1. There was no association of age and reporting
of allodynia with spontaneous attacks (OR: 0.967, 95%
CI: 0.880–1.062 P = 0.477), no association with headache
frequency and reporting allodynia with spontaneous at-
tacks (OR: 1.109, 95% CI: 0.970–1.268, P = 0.132).
There was a signiﬁcant association between reporting trig-
gered allodynia and the presence of allodynia with spon-
taneous attacks (OR: 8.151, 95% CI: 1.984–33.479,
P = 0.004). There was no association between years
lived with migraine and spontaneous allodynia within
this model (OR: 1.035, 95% CI: 0.944–1.136,
P = 0.464). When the same analysis was done for the pres-
ence of triggered allodynia at Visit 1, there was no asso-
ciation of either age (OR: 1.051 95% CI: 0.958–1.154,
P = 0.703) or headache days (OR: 1.028 95% CI: 0.892–
1.184, P = 0.703). There was no effect of years lived with
migraine on the reporting of triggered allodynia within
this model (OR: 0.980, 95% CI: 0.896–1.073,
P = 0.665). There was no effect of diagnosis, either
Table 2 Summary of responses of all patients who reported spontaneous cranial allodynia with their migraine
attacks
Case # Headache days
per month (/30)
Triggered
allodynia V1
Triggered
allodynia V2
Triggered
allodynia V3
Response to treatment
1 10 N (HA) - - -
2 22 Y N Y Y (ASA)
5 10 Y - - Y (ASA)
6 15 Y Y - Y (ASA)
8 7 N (HA) Y Y Y (ASA) Not V3
11 10 N (no HA) - - -
12 8 Y (but no HA) - - Not treated as no headache
17 10 N (HA) - - -
21 3 N (HA) - - -
24 10 Y Y Y Y (ASA) Not V3
26 15 N (HA) - - -
31 22 N (HA) N (HA) - -
33 4 Y Y - Y (Suma)
34 6 Y Y - Y (Suma)
37 12 Y - - Y (Suma)
42 6 Y N (HA) - N (Suma)
43 16 Y Y - Y (Suma) V1
45 15 N (HA) - - -
46 2 Y Y - N (Suma)
49 8 Y - - Y (Suma)
50 12 Y Y - Y (Suma) V1
51 5 N (no HA) - - -
53 4 Y Y - Y (Suma)
ASA = 1 g i.v. aspirin; HA = headache triggered with nitroglycerine; N = no; Suma = 6 mg sumatriptan s.c.; Y = yes with headache (HA) unless stated otherwise; V1–3 = visit number
with nitroglycerine exposure. Dash represents missing data for that individual. Sumatriptan treated patients only had two exposures to nitroglycerine.
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episodic migraine without aura, episodic migraine with
aura or chronic migraine, on reporting spontaneous trig-
gered allodynia (P = 0.68). This ﬁts with the regression
analysis that there did not seem as strong an association
of the positive reporting with triggered allodynia with
increasing headache days.
Preclinical studies
Neuronal identification and properties
Electrophysiological recordings were made from 44 neu-
rons that responded to electrical stimulation of the trigem-
inal afferent innervation of the dura mater, and with
cutaneous facial receptor ﬁelds that included predominantly
the ﬁrst division of the trigeminal nerve, and on occasion
also the second and third division. Of these 44, 29 (25 wide
dynamic range, three high-threshold, and one low-thresh-
old) exhibited a combination of either reproducible burst
(action potentials in close proximity of each other) of
discharges at 3–20ms (Ad ﬁbre) or 3–30ms (both Ad and
C-ﬁbre), with also a unitary (single isolated action poten-
tials) discharge at 20–80ms (C-ﬁbre), which were classiﬁed
as receiving both Ad and C-ﬁbre inputs. Neuronal bursts
(n = 15; all wide dynamic range) exhibiting only early dis-
charge responses at 3–20ms (Ad ﬁbre), were classiﬁed as
receiving only Ad-ﬁbre inputs (Fig. 1A and B). Neurons
were located in mainly nociceptive-speciﬁc superﬁcial
(laminae I and II) and deeper layers (laminae V and VI)
of the dorsal horn of the trigeminocervical complex at
range of depth of 200–1200mm.
Through all animals/groups studied the average baseline
ongoing spontaneous ﬁring rate was 27.1  2Hz, and there
was no signiﬁcant difference across the different groups
[F(3,40) = 2.7, P = 0.062]. There was also no signiﬁcant
difference at baseline between all groups for dural-evoked
Ad-ﬁbre units [F(3,43) = 1.2, P = 0.3], or unitary C-ﬁbre
discharges [F(3,15) = 1.2, P = 0.35], with an average base-
line of 7.9  0.2 and 1.3  0.2 action potential spikes per
sweep (s/s), respectively. There was also no signiﬁcant
Table 3 Summary of responses of all patients given nitroglycerine who did not previously report spontaneous
allodynia
Case # Headache days
per months (/30)
Triggered
allodynia V1
Triggered
allodynia V2
Triggered
allodynia V3
Response to treatment
3 2 N (HA) N (HA) N (HA) -
4 1 N (HA) N (HA) - -
7 15 Y Y Y Y (ASA) Not V2
9 5 N (HA) - - -
10 2 N (HA) - - -
13 4 N (no HA) - - -
14 12 N (HA) N (HA) N (HA) -
15 7 N (no HA) - - -
16 10 N (HA) N (HA) N (HA) -
18 4 N (no HA) - - -
19 6 N (no HA) - - -
20 5 N (HA) N (HA) Y Y (ASA)
22 12 N (HA) - - -
23 6 N (HA) - - -
25 0 N (no HA) - - -
27 15 N (HA) Y N N (ASA)
28 8 N (no HA) - - -
29 4 N (HA) - - -
30 16 N (HA) N (HA) - -
32 15 Y - - N (Suma)
35 4 N (HA) Y - Y (Suma)
36 15 N (HA) N (HA) - -
38 16 N (HA) - - -
39 8 N (HA) Y - Y (Suma)
40 10 Y - - Y (Suma)
41 6 N (HA) - - -
44 6 Y Y - Y (Suma)
47 15 N (HA) - - -
48 5 N (HA) - - -
52 10 N (HA) - - -
ASA = 1 g i.v. aspirin; HA = headache triggered with nitroglycerine; N = no; Suma = 6 mg sumatriptan s.c.; Y = yes with headache (HA) unless stated otherwise; V1–3 = visit number
with nitroglycerine exposure. Dash represents missing data for that individual. Sumatriptan treated patients only had two exposures to nitroglycerine.
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difference at baseline between groups in response to both
innocuous (H3 = 4.3, P = 0.23) and noxious (H3 = 0.6,
P = 0.91) somatosensory stimulation of the facial receptive
ﬁeld. The physiological characteristics of this neuronal
population are similar to previous studies (Akerman and
Goadsby, 2015).
Blood pressure responses
Nitroglycerine (1 and 10mg/kg) and VIP (150 mg/kg) each
caused a signiﬁcant drop in blood pressure (range 8.7–
53.9mmHg) upon administration. There was no signiﬁcant
difference in the blood pressure drop between nitroglycer-
ine (10mg/kg) and both nitroglycerine [1 mg/kg,
t(33) = 1.9, P = 0.071] and VIP [t(33) = 1.6, P = 0.13].
There was also no difference in the duration of the blood
pressure drop before it returned to baseline across the three
groups [F(2,43) = 0.23, P = 0.78], which was 1323.6  91 s
across all groups.
High-dose nitroglycerine causes
delayed activation of central
trigeminocervical neurons
Overall nitroglycerine (10mg/kg) caused a signiﬁcant in-
crease in ongoing spontaneous trigeminal neuronal ﬁring
over the ﬁrst 60min [F(3.1,40.9) = 3.7, P = 0.018, n = 14,
31.2  4Hz to 42.0  6 Hz], speciﬁcally after 30min
[t(13) = 3.2, P = 0.007], which remained signiﬁcant up to
at least 3 h [F(6,78) = 7.3, P = 0.001, up to 50.4  7Hz;
Fig. 2A–E]. Using the critical ratio test (Nagler et al.,
1973), which in effect implies that a 30% change from
baseline is considered signiﬁcant, and 10–30% change un-
classiﬁed, in eight rats there was no change in ongoing
ﬁring after 30min. These included six neuronal responses
classiﬁed as receiving both Ad and C-ﬁbre inputs, and two
with Ad-ﬁbre only, all wide dynamic range. At 1 h there
were still four rats that had not reached this critical ratio.
However, across the 3 h, all neuronal responses exhibited a
signiﬁcant increase from baseline based on this critical
ratio. Neither nitroglycerine [1 mg/kg, F(1.9,15.4) = 0.28,
P = 0.75, n = 9] nor VIP [150 mg/kg, F(1.8,14.3) = 0.92,
P = 0.41, n = 9] caused any increase in ongoing ﬁring,
over the ﬁrst 60min or up to 3 h (Fig. 2A–E), and in
each group no animals exhibited a signiﬁcant increase in
ongoing ﬁring based on critical ratio. Therefore, only the
higher dose of nitroglycerine causes signiﬁcant changes to
ongoing spontaneous ﬁring, and this was not driven by
cardiovascular or cerebrovascular changes, whereas activity
with lower dose nitroglycerine and VIP does not change
beyond normal.
High dose nitroglycerine causes
delayed hypersensitivity of central
trigeminocervical neurons to cephalic
somatosensory stimulation
This increase in ongoing neuronal ﬁring manifested as
signiﬁcant hypersensitive responses of the same trigemino-
cervical neurons to dural stimulation. Nitroglycerine
(10mg/kg) caused a signiﬁcant increase over 3 h in the
number of dural-evoked action potential spikes for all
neuronal discharges within the Ad-ﬁbre range, whose la-
tency was extended to also include ‘fast’ C-ﬁbre responses
[F(2.7,36.7 = 14.7, P = 0.001, n = 14] that was signiﬁcant
after 60min [t(13) = 3.6, P = 0.003, from 8.0  0.4 to
9.2  0.6 s/s], and remained signiﬁcant until at least 3 h
[t(13) = 8.0, P = 0.001, 9.8  0.5 s/s]. There was also a
signiﬁcant increase in action potential spikes for unitary
discharges within the ‘slow’ C-ﬁbre range [F(6,36) = 3.5,
P = 0.08, n = 7] that began after 90min [t(6) = 2.4,
P = 0.024, from 1.4  0.3 to 3.5  0.9 s/s] and remained
signiﬁcant until at least 3 h [t(6) = 2.7, P = 0.034,
2.6  0.5 s/s]. Neither low dose nitroglycerine (1mg/kg)
nor VIP (150 mg/kg) had any signiﬁcant effects on bursts
Figure 1 Original tracings characterizing subtype of
dural-evoked trigeminocervical neuronal fibres. Example
tracings illustrate (A) early reproducible neuronal discharges clas-
sified as receiving only Ad-fibre input (520 ms latency; ‘fast’ neur-
onal responses), and (B) reproducible neuronal spikes with
extended discharges beyond 20 ms latency, which were classified as
receiving both Ad and C-fibre inputs (530 ms latency; ‘fast’ neur-
onal responses), and also with later unitary discharges that were
also classified as receiving C-fibre input (‘slow’ neuronal responses).
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Figure 2 High dose nitroglycerine causes delayed activation of central trigeminocervical neurons. (A) Experimental set-up for
electrophysiological recording of neurons in the trigeminocervical complex (TCC), which respond to electrical stimulation of the trigeminal
innervation of the dural meninges, with a cutaneous facial receptive field (shaded area) characterization in the ophthalmic dermatome. (B) Time
course changes in ongoing spontaneous trigeminocervical neuronal firing [action potentials per second (Hz)] in response to nitroglycerine (NTG,
1 and 10 mg/kg, s.c.) and vasoactive intestinal peptide (VIP, 150 mg/kg, s.c.). The data have been normalized to represent the percentage change
from baseline, and are expressed as mean  SEM. (C–E) Representative peri-stimulus time histograms with a single animal for each group
demonstrating ongoing spontaneous trigeminocervical neuronal firing before (C) nitroglycerine (1 mg/kg), (D) nitroglycerine (10 mg/kg) and
(E) VIP administration, and at 90 min and 3 h post-infusion. The numbers indicate the mean firing [spikes per second (Hz)] over the displayed time
period, green neuronal firing indicates baseline and no change in responses, blue neuronal firing indicates a significant increase in neuronal firing.
Beneath each of these is a box-and-whisker plot representing median and interquartile range (IQR), with 5th and 95th percentile, and individual
points beyond this, of all trigeminocervical complex neurons studied per group, sampled at 1 h intervals after drug administration. Nitroglycerine
(10 mg/kg, n = 14) caused a delayed and significant increase in ongoing spontaneous trigeminal neuronal firing that is significant (*P5 0.05) after
60 min and continues until at least 3 h, whereas nitroglycerine (1 mg/kg, n = 9) and VIP (n = 9) do not cause any changes over 3 h. MMA = middle
meningeal artery; TG = trigeminal ganglion.
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of ‘fast’ Ad/C-ﬁbre neuronal discharges [nitroglycerine,
F(6,48) = 0.7, P = 0.55, n = 9; VIP, F(6,48) = 0.7,
P = 0.55, n = 9] or ‘slow’ C-ﬁbre unitary discharges [nitro-
glycerine, F(2.0,5.9) = 0.6, P = 0.6, n = 4; VIP, not enough
data for analysis] (Fig. 3A and B).
There was also a hypersensitive response to cutaneous
facial stimulation after nitroglycerine (10mg/kg), with
increased neuronal ﬁring to innocuous brush
[F(1.9,18.8) = 24.4, P = 0.001, n = 11] and noxious pinch
[F(4,40) = 7.0, P = 0.001, n = 11]. Neuronal responses to
cutaneous innocuous brush [t(10) = 4.0, P = 0.001, n = 11]
and noxious pinch [t(10 = 3.4, P = 0.007, n = 11] were sig-
niﬁcantly increased compared to baseline after 45 and
135min, respectively, and continued until at least 3 h
[Fig. 3C–G). However, nitroglycerine (1mg/kg) and VIP
did not cause hypersensitive neuronal responses to either
innocuous brush [nitroglycerine, F(4,32) = 0.68, P = 0.61,
n = 9; VIP, F(4,32) = 0.81, P = 0.53, n = 9] or noxious
pinch [nitroglycerine, F(4,32) = 0.2, P = 0.94; VIP,
F(1.7,13.2) = 1.8, P = 0.21] of the cutaneous facial
receptive ﬁeld.
Naratriptan reverses nitroglycerine-
evoked neuronal responses
In a separate series of experiments we determined whether
naratriptan (10mg/kg, i.v.) is able to reverse the effects of
nitroglycerine (10mg/kg) on central trigeminovascular neu-
rons, predicted to be effective based on clinical outcomes.
Here, naratriptan was administered at the 135min time
point, and responses followed for a further 45 mins.
Before conducting data analysis of the effects of naratriptan
we ﬁrst conﬁrmed that nitroglycerine produced a statistic-
ally signiﬁcant increase in neuronal response at 120min
(summarized in Table 4 and Fig. 4A–F). Subsequently, nar-
atriptan signiﬁcantly reversed the increase in ongoing spon-
taneous trigeminal neuronal ﬁring [F(2.4,26.8) = 6.9,
P = 0.002, n = 12], speciﬁcally after 25min [t(11 = 3.0,
P = 0.012] that was maintained through 45min from
48.8  9Hz prior to naratriptan to 23.4  5Hz after
45min. The dural-intracranial hypersensitive neuronal
responses were also signiﬁcantly inhibited by naratriptan
for bursts of neuronal discharges within the Ad-ﬁbre
range [3–20ms; F(3.2,35.6) = 8.2, P = 0.001], speciﬁcally
after 10min [t(11 = 4.6, P = 0.001] that was maintained
through 45min (9.2  0.6 prior to naratriptan to
7.4  0.8 s/s after 45min). Unitary discharges within the
C-ﬁbre range were also signiﬁcantly inhibited by naratrip-
tan [20–80ms; F(2.3,11.7) = 4.2, P = 0.037, n = 6], speciﬁc-
ally after 5min [t(6 = 3.7, P = 0.014, n = 7] that was
maintained through 45min (4.5  0.7 to 2.0  0.4 s/s).
The extracranial cutaneous facial hypersensitivity mediated
by nitroglycerine was also signiﬁcantly inhibited by treat-
ment with naratriptan [n = 10, innocuous brush, t(9) = 3.8,
P = 0.004; noxious pinch, t(9) = 2.9, P = 0.018].
Discussion
Here, we demonstrate reliable triggering of migraine head-
ache with nitroglycerine and reproduction of cranial allo-
dynia in patients with allodynia with their spontaneous
migraine. Further, when patients were re-exposed to nitro-
glycerine on a second or third visit, there was 450% re-
producibility of triggering cranial allodynia in these
patients. The data with sumatriptan also clearly show allo-
dynia can be aborted by a triptan in nitroglycerine-trig-
gered migraine. Whilst the sample size of human subjects
exposed to nitroglycerine here was not sufﬁcient for exten-
sive subgroup analysis of migraine subtypes, it is clear that
nitroglycerine can acutely provoke cranial allodynia in
humans and this is consistent with patient self-reports of
acute allodynia associated with episodic migraine attacks
and the lack of association of the presence of allodynia
with effective treatment response (Cady et al., 2009). In
addition, these data complement similar data that triptans
can abort cranial allodynia associated with spontaneous
migraine (Goadsby et al., 2008; Diaz-Insa et al., 2011),
and aspirin has a similar effect as shown in this study.
Whilst the clinical study has been able to demonstrate a
triptan and NSAID-response of nitroglycerine-induced cra-
nial allodynia, apart from the response of allodynia to each
treatment and the time to headache abortion, no additional
differentiating data for the two treatment groups were ob-
tained. Further, nitroglycerine can trigger activation and
sensitization of trigeminocervical neurons in rat, which is
not seen with the potent vasodilator VIP and this is also
aborted with a triptan. The data suggest that nitroglycerine
can be used as an effective and reliable trigger of migraine-
associated cranial allodynia, and provides a valuable op-
portunity to study pathophysiological mechanisms related
to cranial allodynia experimentally.
Triptan treatment has previously been shown to abort
nitroglycerine-triggered migraine-like headache (Afridi
et al., 2005; Juhasz et al., 2005). When administered
either aspirin or sumatriptan in response to nitroglycer-
ine-triggered migraine with cranial allodynia, the majority
of the time patients responded to these treatments with
abortion of both headache and cranial allodynia. No add-
itional differentiating data for the two treatment groups
were obtained. These ﬁndings are consistent with previous
studies demonstrating that the NSAID ketorolac is able to
terminate cutaneous facial allodynia (Jakubowski et al.,
2005a). However, several studies suggest that once cutane-
ous allodynia is established it responds much less to trip-
tans (Burstein et al., 2004; Jakubowski et al., 2005a). It is
hypothesized that this reﬂects the development of sensitiza-
tion of central trigeminovascular neurons, and the conse-
quent symptoms of extracranial cutaneous hypersensitivity
(Burstein and Jakubowski, 2004; Levy et al., 2004). It has
led to a view in headache medicine that migraine responds
most successfully when treated with triptans early into an
attack, speciﬁcally before allodynia is established.
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Figure 3 High dose nitroglycerine causes delayed neuronal hypersensitive responses of central trigeminocervical neurons to
somatosensory stimulation. Box-and-whisker plots representing median and IQR, and the 5th and 95th percentile, with individual points
beyond this, of (A) grouped data of intracranial dural-evoked bursts of trigeminocervical neuronal discharges that include inputs in the Ad-fibre
range (3–20 ms; ‘fast’ neuronal responses), and also those whose latencies were extended and therefore also receive inputs that include both Ad
and C-fibres (3–30 ms; ‘fast’ neuronal responses), and (B) intracranial dural-evoked unitary discharges within the C-fibre latency range (20–80 ms;
‘slow’ neuronal responses), in response to nitroglycerine (1 and 10 mg/kg, s.c.) and VIP (10mg/kg, s.c.) administration. Nitroglycerine (10 mg/kg)
caused a delayed hypersensitivity in neuronal responses to electrical stimulation of the trigeminal innervation of the dural meninges, for ‘fast’
(n = 14) and ‘slow’ (n = 7) neuronal responses that is significant compared to baseline after 1 and 2 h (*P5 0.05), respectively. Nitroglycerine
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In a double-blind, placebo-controlled, parallel-group,
multicentre trial spontaneous migraine treated with almo-
triptan early, when pain was mild, with the endpoint of
pain-free by 2 h, was signiﬁcantly more effective than
when pain was moderate-severe. Furthermore, the pres-
ence of allodynia did not alter the efﬁcacy of almotriptan
to reach pain-free with early/mild or moderate/severe mi-
graine. Allodynia was therefore not a reliable predictor of
lack of response to a triptan in these spontaneous mi-
graine attacks, but rather severity of pain (Goadsby
et al., 2008; Diaz-Insa et al., 2011). These data are con-
sistent with similar studies using rizatriptan (Cady et al.,
2007), and almotriptan and NSAIDs (Schoenen et al.,
2008). Moreover, severity of pain rather than time to
treatment was the signiﬁcant predictor of response
across a meta-analysis of the eletriptan studies (Diener
et al., 2008). These data in spontaneous migraine share
similarities with the nitroglycerine-triggered data we pre-
sent, with triptan-responsive cranial allodynia accompany-
ing migraine headache. The difference in response to
triptans from these studies is a challenge. It may reﬂect
variation both between patients and within patients from
attack to attack.
Comparing data from different studies can be hazard-
ous, and complicated by differing primary objectives and
study design/methods. Focusing on pain severity, in the
current study the criterion for treatment was when pain
reached moderate-severe intensity, either with or without
cranial allodynia, rather than early or late into an attack
(117  10min). So, all triptan-responsive cranial allodynia
was categorized as moderate-severe. In the triptan-unre-
sponsive study, pain intensity was also likely categorized
as moderate-severe throughout, whether treatment was
early or late. However, in their early treatment group
(1 h after pain onset) pain levels were statistically no dif-
ferent between the allodynic or non-allodynic groups. In
the late treatment arm (4 h after pain onset) the allodynic
group had signiﬁcantly higher pain intensity (likely cate-
gorized as severe, 8.3 on a 0–10 scale) compared to the
non-allodynic group (5.9) (Burstein and Jakubowski,
2004). It is not possible to determine whether this differ-
ence impacted the success of using a triptan, but in both
treatment groups triptan use was signiﬁcantly more likely
to yield pain-free results in the non-allodynic group. It is
also noteworthy that assessment of cranial allodynia was
different through these studies. Burstein and colleagues
(2004) used quantitative sensory testing (QST) measuring
deﬁnitive cold, heat and mechanical pain thresholds. In
our study, and the almotriptan study, cranial allodynia
was assessed via a similarly phrased questionnaire. These
surveys were both in line with validated questionnaires
(Jakubowski et al., 2005b; Ashkenazi et al., 2007) deter-
mined to identify reliably allodynic or non-allodynic pa-
tients, compared to QST. We believe that our conclusion
that nitroglycerine triggers triptan-responsive cranial allo-
dynia in migraine patients is therefore valid compared to
these studies.
Activation, or hypersensitive neuronal responses, of the
dural trigeminovascular innervation is thought to be
involved in the pathogenesis of throbbing migraine-like
Figure 3 Continued
(1 mg/kg) and VIP did not cause any change in neuronal responses. Box-and-whisker plots of (C) innocuous and (D) noxious cutaneous facial-
evoked stimulation following nitroglycerine (1 and 10 mg/kg) and VIP. Representative peristimulus time histograms from a single animal for each
group depicting trigeminocervical neuronal firing in response to innocuous brush and noxious pinch of the cutaneous facial receptor field before
nitroglycerine (10 mg/kg, E), nitroglycerine (1 mg/kg, F) and VIP (G), and at 90 min and 3 h post-infusion. The numbers in parentheses indicate the
mean firing (Hz) in response to stimulation (shaded area), green neuronal firing indicates baseline and no change in responses, blue neuronal firing
indicates a significant increase in neuronal firing. Nitroglycerine (10 mg/kg) caused a delayed and significant increase in neuronal responses to
innocuous and noxious facial cutaneous stimulation in the ophthalmic dermatome after 45 and 135 min, respectively. Nitroglycerine (1 mg/kg) and
VIP did not cause any changes. *P5 0.05 significant compared to baseline.
Table 4 Summary of trigeminocervical neuronal data at baseline and after 2 h, in response to nitroglycerine (10mg/
kg, s.c.) for naratriptan group
Naratriptan (10mg/kg)
Spontaneous activity (Hz)
Baseline 31.2  4
Post nitroglycerine 2 h 47.5  8 [F(2.2,24.6) = 5.8, *P = 0.007, n = 12]
Dural-evoked Ad and C-fibre clusters (AP/Stim)
Baseline 7.6  0.4
Post nitroglycerine 2 h 9.3  0.5 [F(5,55) = 9.6, *P = 0.001, n = 12]
Dural-evoked unitary C-fibre discharges (AP/Stim)
Baseline 1.6  0.3
Post nitroglycerine 2 h 4.0  0.9 [F(5,25) = 8.1, *P = 0.001, n = 6]
AP/Stim = number of action potential spikes per stimulation; *P5 0.05 significance from baseline.
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Figure 4 Naratriptan reverses nitroglycerine-evoked activation of central trigeminovascular neurons and hypersensitive re-
sponses to somatosensory stimulation. Time course of (A) the mean ongoing spontaneous trigeminal neuronal firing [action potential spikes
per second (Hz)], (B) grouped data of intracranial dural-evoked bursts of trigeminocervical neuronal discharges that include inputs in the Ad-fibre
range (3–20 ms; ‘fast’ neuronal responses), and also those whose latencies were extended and therefore also receive inputs that include both Ad
and C-fibres (3–30 ms; ‘fast’ neuronal responses), and (C) intracranial dural-evoked unitary discharges within the C-fibre latency range (20–80 ms;
‘slow’ neuronal responses). All are in response to nitroglycerine (10 mg/kg, s.c.) and after treatment with the migraine abortive, 5-HT1B/1D
receptor agonist, naratriptan (10 mg/kg, i.v.). In each panel the data have been normalized to represent a percentage change from baseline and are
expressed as mean  SEM. Naratriptan significantly aborted the increase in ongoing spontaneous neuronal firing, and the hypersensitive neuronal
responses to dural-intracranial electrical stimulation for ‘fast’ and ‘slow’ neuronal responses. (D) Original tracings of a single sweep (stimulus) in
the same animal for a dural-evoked Ad-fibre (‘fast’) neuronal burst and unitary C-fibre (‘slow’) discharge at baseline, 2 h after nitroglycerine
administration, and 45 min after subsequent administration of the migraine abortive naratriptan. Both the Ad-fibre neuronal burst and unitary
C-fibre discharge become hypersensitive to dural stimulation after nitroglycerine, as evidenced by an increase in the number of action potential
spikes at each latency. This is attenuated after treatment with naratriptan. Box-and-whisker plots representing median and IQR, and the 5th and
95th percentile, with individual points beyond this, of time course changes in trigeminocervical neuronal firing, in response to (E) innocuous and
(F) noxious cutaneous stimulation of the facial receptive field after nitroglycerine, followed by treatment with naratriptan. The hypersensitivity in
neuronal responses to both innocuous and noxious cutaneous facial stimulation 2 h after nitroglycerine is attenuated by naratriptan. *P5 0.05
represents a statistically significant difference compared to baseline (0 min). #P5 0.05 represents a statistically significant difference compared to
the time point just prior to administration of naratriptan, which was given post nitroglycerine 135 min. Arrowhead in A–C indicates time at which
naratriptan was administered. All data are represented as mean  SEM.
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head pain (Penﬁeld and McNaughton, 1940; Ray and
Wolff, 1940). Likewise, symptoms of cranial allodynia in
migraine are thought to be mediated by sensitization of
these dural-responsive central trigeminovascular neurons
that receive convergent inputs from facial cutaneous areas
(Burstein et al., 1998). These mechanisms can be modelled
in animals using dural nociceptive activation, either via
electrical stimuli (Goadsby and Zagami, 1991) or chemical
mediators (Burstein et al., 1998). A further aim of this
study was therefore to determine that nitroglycerine medi-
ates this underlying neurophysiological mechanism. We
demonstrate that only high dose nitroglycerine causes a
sustained increase in ongoing spontaneous ﬁring of both
Ad and C-ﬁbre trigeminal neurons that innervate the
dural vasculature and cutaneous facial region. This mani-
fests as prolonged neuronal hypersensitivity to cephalic
intracranial-dural and extracranial-cutaneous somatosen-
sory stimulation; a neuronal phenotype indicative of central
trigeminovascular sensitization. To translate these data fur-
ther, we found that naratriptan reversed intracranial-dural
hypersensitivity. Naratriptan also reversed measures that
reﬂect more intrinsic activity; increased ongoing spontan-
eous ﬁring and hypersensitivity to cutaneous-facial stimula-
tion. This suggests that triptans act via post-synaptic
inhibition directly on second-order central neurons in the
trigeminocervical complex, previously conﬁrmed (Goadsby
et al., 2001), as well as peripherally to block pain signals
from the dura mater to central trigeminovascular neurons.
Overall, these data suggest that nitrergic-induced mechan-
isms can mediate the neurophysiological changes taking
place along the migraine pain pathway, which result in
throbbing head pain and cranial allodynia, and triptans
can abort these mechanisms. This provides an explanation
for the cephalic migrainous symptoms in nitroglycerine-
mediated migraine, and potentially describes a mechanism
in mediating spontaneous migraine with cranial allodynia
that does respond to triptan.
Together, these data suggest that patients with migraine-
associated cranial allodynia can be grouped into those re-
sponsive to triptan treatment, and those where cutaneous
allodynia predicts lack of triptan efﬁcacy. This points to at
least two mechanisms in mediating the neurophysiological
changes that result in migraine symptoms, and potentially
distinguishing migraine subgroups. Further, preclinically
there are now two approaches validated to help dissect
and characterize the mechanism of these differences. First,
placement of an inﬂammatory soup on the dura mater
causes a neuroinﬂammatory cascade in the local dural
microenvironment. This causes intrinsic phenotypic neur-
onal changes to central trigeminovascular neurons via acti-
vation and sensitization of primary trigeminal afferents,
resulting in cephalic migraine symptoms (Strassman et al.,
1996; Burstein et al., 1998). These intrinsic changes are un-
responsive to triptan treatment (Burstein and Jakubowski,
2004). It seems that with nitroglycerine, and potentially
many spontaneous migraine attacks, a different mechanism
may be involved.
While we cannot deﬁnitively explain the mechanism of
nitroglycerine-mediated migraine, several studies help us to
exclude some options. Nitroglycerine is a potent vasodila-
tor in humans (Hansen et al., 2007; Schoonman et al.,
2008) and rodents (Akerman et al., 2002), but previous
studies conﬁrm that dural vascular mechanisms are unlikely
to mediate trigeminovascular sensitization (Akerman and
Goadsby, 2015) and migraine symptoms (Amin et al.,
2013). Our data support this as neither low dose nitrogly-
cerine nor VIP produced neuronal changes, despite similar
vascular changes to high dose nitroglycerine. Importantly,
VIP does not trigger migraine in migraine patients
(Rahmann et al., 2008). Nitroglycerine also mediates a
dural inﬂammatory cascade, including upregulation of in-
ducible NO synthase (iNOS), IL-1b, and IL-6 in dural
macrophage, and dural plasma leakage (Reuter et al.,
2001). The nitroglycerine-induced plasma leakage was atte-
nuated by a speciﬁc iNOS inhibitor, but iNOS inhibition
was not efﬁcacious in migraine treatment (Hoivik et al.,
2010; Hoffmann and Goadsby, 2012). Local inﬂammatory
changes in the dural microenvironment are therefore prob-
ably not involved.
Nitroglycerine acts as a nitric oxide (NO) donor, which is
a highly volatile agent that readily crosses the blood–brain
barrier, diffusing into brain cells (Moncada et al., 1991). It
activates neuronal and pro-inﬂammatory mechanisms
within various brainstem and diencephalic nuclei
(Tassorelli and Joseph, 1995; Tassorelli et al., 2007)
involved in migraine pathophysiology, and thought to
modulate trigeminovascular neurons. An increase in on-
going ﬁring of neurons along the dural-trigeminal pain
pathway is likely to translate to the development of intra-
cranial headache, whereas intracranial hypersensitivity
translates to the throbbing nature of pain and exacerbation
of headache with physical activity. It is noteworthy that
nitroglycerine seems to mediate differential responses on
durally-innervated primary afferent and second-order trige-
minovascular neurons. It does not alter ongoing ﬁring of
primary afferent neurons, despite causing intracranial
hypersensitivity (Zhang et al., 2013), whereas previous stu-
dies have shown, and we conﬁrm, that it activates central
trigeminovascular neurons (Koulchitsky et al., 2004, 2009).
The authors (Zhang et al., 2013) speculate that nitroglycer-
ine is primarily acting on central mechanisms, either
second-order trigeminovascular neurons directly, or other
central nuclei, to provoke the underlying neurophysio-
logical mechanisms within trigeminovascular neurons,
such as sensitization, which leads to migrainous symptoms,
including enhanced response of peripheral noxious inputs.
This may explain why the enhanced response of primary
afferent neurons to nitroglycerine seems to be delayed
beyond the time it mediates changes of central trigemino-
vascular neurons. These mechanisms are therefore more
likely involved in mediating triptan-responsive cranial allo-
dynia in spontaneous migraine.
There are important limitations of the translational data.
The nitroglycerine doses in the preclinical study are
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considerably higher than those used in the clinical study. It
is now acknowledged that human dosing does not directly
translate to animal doses (Reagan-Shaw et al., 2008).
Many factors need to be taken into account to calculate
the preclinical dose, including time to maximum effect, rate
of metabolism, and body surface area. All usually increase
the required effective dose in small animals. While the
doses used are still relatively high, they are similar to pre-
vious studies (Tassorelli and Joseph, 1995; Marone et al.,
2018). Furthermore, our data are validated by the fact that
the lower dose did not alter any measure of neuronal re-
sponse, and the higher dose responded to triptan treatment,
similar to that found in patients. Another issue relates to
timing of response after nitroglycerine. Human studies gen-
erally report that migraine is delayed by 4–5 h after nitro-
glycerine. While we report the delay to moderate-severe
headache of up to 278min, the average time to reach
moderate-severe head pain was actually 117min, with the
earliest time for a single patient at 20min. Indeed, nearly
one-quarter of the patients where migraine headache was
triggered reached moderate-severe intensity by 60min. In
the preclinical study signiﬁcant change in ongoing ﬁring
of central trigmeinovascular neurons was seen at 30min,
but in 8/14 rats this was not above a critical ratio (530%
increase). Indeed, even at 60min there were still four ani-
mals where ongoing ﬁring had not signiﬁcantly increased.
In a recent animal study reported, the authors used a
human-like dose of nitroglycerine, and observed a delayed
intracranial hypersensitivity in primary afferent neurons of
2–3 h (Zhang et al., 2013), yet no observations of increase
in ongoing discharge, a likely correlate of the development
of intracranial headache, were observed. While the dose
and the timings in our study do not directly overlap, we
believe there is sufﬁcient evidence to validate that the pre-
clinical data translate to the ﬁndings clinically.
Another potential limitation to translating the data is that
different triptans were used; the reasons for which are out-
lined in the ‘Materials and methods’ section. All triptans
act via 5-HT1B/1D receptors, with subtle variations in
speciﬁc binding afﬁnities, and efﬁcacy at other 5-HT1 re-
ceptors (Tfelt-Hansen et al., 2000). Naratriptan is described
as having ‘a very similar pharmacological proﬁle to that of
sumatriptan’ (Connor et al., 1997), but is perhaps a little
more potent with better oral bioavailability. Naratriptan is
also more lipophilic than sumatriptan, suggesting it may
have greater brain penetrance, but deﬁnitive studies relating
to this are not available. One of the major ﬁndings here is
that sumatriptan inhibited nitroglycerine-induced cranial
allodynia that accompanied migraine headache, and it has
previously been shown to inhibit nitroglycerine-induced
hind-paw allodynia in mice (Pradhan et al., 2014).
Allodynia is thought to be mediated by central neuronal
sensitization. Therefore, despite potentially limited brain
penetrance, sumatriptan is still able to abort these symp-
toms. Given that both sumatriptan and naratriptan were
administered via parenteral routes, they have similar
pharmacological proﬁles, and while naratriptan aborted
signatures of trigeminovascular sensitization, sumatriptan
aborted a likely phenotypic outcome, cranial allodynia, at
the very least we believe that naratriptan is acting in a
similar mechanistic way to sumatriptan to abort these neur-
onal and phenotypic outcomes. Therefore, we do not be-
lieve that using different triptans in the different arms of
this study affected either the outcomes or their interpret-
ation in this study.
In summary, it is clear that the migraineurs’ experience of
their attack can be very individual, and this is reﬂected in
how they respond to treatments. Nitroglycerine as a human
model of migraine shares many phenotypic similarities
common to spontaneous migraine, including now
triptan-responsive cranial allodynia, which also translates
into underlying mechanisms from preclinical studies.
Combined with data from previous studies, it suggests
there are several mechanisms mediating the underlying
neurophysiological changes that result in migraine cephalic
symptoms, translated by different preclinical approaches,
where response to triptans is a differentiating feature. We
clearly demonstrate a mechanism where migraine-asso-
ciated cranial allodynia is successfully aborted by a triptan,
which correlates with similar ﬁndings in spontaneous mi-
graine. This contrasts with previous ﬁndings of a subgroup
of patients where the presence of allodynia is predictive of
triptans failing to provide adequate relief from migraine
symptoms. We reﬂect that there is much to be gained in
acknowledging that several preclinical approaches can, and
should, be used to study pathophysiological mechanisms
related to a disorder. Here we have validated an effective
and reliable method to trigger experimentally migraine-like
cranial allodynia that responds to abortive treatment,
which shares a phenotype common to many spontaneous
migraine attacks that is responsive to triptan treatment.
This approach also translates preclinically and can there-
fore be used to dissect the neurophysiological mechanisms
of sensitization relevant to provocative migraine studies,
but also spontaneous migraine, and as a tool in drug de-
velopment and discovery efforts.
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